Stanford Cancer Institute Directory
Translational Oncology Profiles
Showing 21 - 30 of 48
The George A. and Hilda M. Daubert Professor in Chemistry
Eric Kool received his Ph.D. in Chemistry from Columbia University and did postdoctoral work in nucleic acids chemistry at Caltech. He started his career at the University of Rochester before moving to Stanford in 1999, where he is the George and Hilda Daubert Professor of Chemistry. He teaches Organic Chemistry and Chemical Biology to undergraduate and graduate students. The Kool lab uses the tools of chemistry to study the structures, interactions and biological activities of nucleic acids and the enzymes that process them. Molecular design and synthesis play a major role in this work, followed by analysis of structure and function, both in test tubes and in living systems. These studies are aimed at gaining a better basic understanding of biology, and applying this knowledge to practical applications in biomedicine. As part of this research, members of the group synthesize designer nucleobases and nucleotides, with unusual properties such as fluorescence, enzyme reactivity, or altered shape and H-bonding ability. We use these as tools to study DNA polymerase enzymes, DNA repair pathways, and RNA modifying enzymes. This work is leading to new probes for diagnosis of cancer, useful fluorescent tags for biology, and fluorescent sensors of many species such as cancer metabolites and toxic metals.
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Dr. Kunz specializes in the treatment of gastrointestinal malignancies with an expertise in the care of patients with neuroendocrine tumors (NETs). She has developed broad investigative programs in the field of neuroendocrine tumors, encompassing clinical trials, population sciences, and translational correlates. She is the Principal Investigator on numerous clinical trials. She is the Director of the Stanford Neuroendocrine Tumor Program. She currently serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel, the Neuroendocrine Tumor Taskforce of the National Cancer institute, the NANETS Guidelines and Executive Committees, and leads the NET Working Group of the Eastern Cooperative Oncology Group (ECOG).
Associate Professor (Research) of Radiation Oncology (Radiation and Cancer Biology) and of Radiology (Molecular Imaging Program at Stanford)
Associate Professor of Medicine (Oncology) at the Stanford University Medical Center
Dr. Massarweh specializes in breast cancer, with a particular expertise in adjuvant therapy for Hormone-Receptor Positive breast cancer, metastatic breast cancer, and male breast cancer. His research background is in studying endocrine therapy action and resistance mechanisms, as well as targeted therapy to overcome it. His outpatient practice is exclusively dedicated to patients with breast cancer and his philosophy is centered around providing his patients with compassionate expert care. Cancer education and promoting clinical practice innovation is an integral part of his academic and leadership mission. Dr. Massarweh is dedicated to healthcare transformation and using novel approaches to enhance integration of clinical care, research, and education, that is driven by patient centered design. RESEARCH INTERESTS Adjuvant therapy for ER-positive breast cancer Endocrine Resistance Breast Cancer in Men Triple Positive Breast Cancer Clinical Trial Design CLINICAL INTERESTS: Metastatic Breast Cancer Hormone Receptor Positive Breast Cancer Breast Cancer in Men Breast Cancer in Pregnant Women Preoperative Endocrine Therapy
Professor of Microbiology and Immunology
For complete and up to date information on this and other items, consult my Curriculum vitae (updated, 12/16), and website; URL: http://www.stanford.edu/~amatin/MatinLabHomePage/MatinLabHome-Page.htm
Associate Professor of Ophthalmology at the Stanford University Medical Center
**DR MRUTHYUNJAYA IS AVAILABLE TO CARE FOR PATIENTS WITH EYE CANCERS AND RETINAL DISEASES** Prithvi Mruthyunjaya MD, MHS is Associate Professor of Ophthalmology at Stanford Univeristy, member of the Vitreoretinal Surgery Service and is the new Director of Ocular Oncology at the Byers Eye Institute. He is a board certified ophthalmologist who has completed two prestigious fellowships: the first in Vitreoretinal Surgery at Duke University and the second in Ocular Oncology at Moorfields Eye Hospital in London, England. He cares for patients with conditions related to cancer of the eye in both adults and children--either benign, pre-cancerous, or eye cancer. These conditions include ocular melanoma, hemangioma, cancers from other parts of the body which spread to the eye, Coats' disease, retinoblastoma, iris tumors (melanoma, cysts, metastatic lesions) and tumors of the conjunctiva including melanoma, and squamous cells carcinoma. He also manages the eye related side effects of chemotherapy treatments. He is an expert in using the most advanced diagnostic tests to make a personalized treatment plan for every patient. With his expertise in retinal surgery, he treats patients with a variety of advanced techniques including small instrument tumor biopsy, vitrectomy, and radiation therapy. As a retinal surgeon, he manages complicated retinal diseases including retinal detachment, macular holes, epiretinal membranes, and diabetic eye disease. His approach to any patient is to provide customized care for every patient and works closely with other experts at the Stanford Cancer Institute. Dr. Mruthyunjaya is actively involved in research in ocular cancer imaging, genetics, and new modalities of tumor biopsy. His passion lies in developing collaborative research networks and training the next generation of vitreoretinal surgeons. His academic contributions were recognized by the Heed, AOS-Knapp and Ronald G Michels foundations the American Society of Retina Specialists with a Senior Honor Award. He was recently listed as one of the worlds 150 most innovative retinal specialists. BIOGRAPHY: Dr. Mruthyunjaya was born in India and moved to Upstate New York at the age of 2. He was selected for the highly prestigious accelerated 6-year medical program completing his undergraduate studies at Rensselaer in 2 years then moving on to complete his medical studies at Albany Medical College where he was elected to the Alpha Omega Alpha honor society. At the Duke Eye Center in Durham, NC, he finished his Ophthalmology residency, Chief Residency, and clinical-research fellowships in Vitreoretinal surgery followed by an Ocular Oncology fellowship at the Moorfields Eye Hosptial in London, UK. As a fellow, he was recognized with the highest nationwide honors by the Heed, AOS-Knapp and Ronald G Michels foundations. He was on faculty at Duke from 2005-16 where developed an integrated Retina-Ocular Oncology program and was named a tenured Associate Professor of Ophthalmology and Radiation Oncology, Medical Director and Director of Ocular Oncology. He has enjoyed moving to the Bay area with his family.